Let’s start up with the current stock price of Bolt Biotherapeutics Inc. (BOLT), which is $8.43 to be very precise. The Stock rose vividly during the last session to $8.51 after opening rate of $7.96 while the lowest price it went was recorded $7.58 before closing at $7.99.Recently in News on November 19, 2021, Bolt Biotherapeutics Announces Changes to its Board of Directors. Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors. With these additions, longtime Director Peter Moldt, Ph.D. is stepping down from the Board of Directors and current Director Jim Healy, M.D., Ph.D. will be assuming the role of Lead Independent Director. You can read further details here
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Bolt Biotherapeutics Inc. shares are logging -80.43% during the 52-week period from high price, and 7.66% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $7.83 and $43.07.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 756377 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Bolt Biotherapeutics Inc. (BOLT) recorded performance in the market was -73.78%, having the revenues showcasing -46.17% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 321.69M, as it employees total of 65 workers.
The Analysts eye on Bolt Biotherapeutics Inc. (BOLT)
During the last month, 0 analysts gave the Bolt Biotherapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 13.27, with a change in the price was noted -6.91. In a similar fashion, Bolt Biotherapeutics Inc. posted a movement of -45.05% for the period of last 100 days, recording 187,784 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BOLT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Bolt Biotherapeutics Inc. (BOLT)
Raw Stochastic average of Bolt Biotherapeutics Inc. in the period of last 50 days is set at 9.41%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 13.18%. In the last 20 days, the company’s Stochastic %K was 8.43% and its Stochastic %D was recorded 8.21%.
Considering, the past performance of Bolt Biotherapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -73.78%. The shares increased approximately by -12.73% in the 7-day charts and went up by -34.90% in the period of the last 30 days. Common stock shares were lifted by -46.17% during last recorded quarter.